Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study

Journal of Comparative Effectiveness Research
Servaas BuijsGert de Voer

Abstract

To investigate the incidence and prevalence and healthcare costs of multiple sclerosis (MS) in the Netherlands by using healthcare claims data. A claims database was analyzed including 26% of the Dutch population. Average prevalence of MS in the Netherlands was 88 per 100,000 inhabitants (males 48, 127 females) and incidence nine per 100,000. Yearly per patient medication costs were highest in the year after the first MS claim and then decreased. Hospital costs were 30% higher in the first year of MS claims than after 3 years of MS claims. The patients often used co-medication, such as antidepressants and antibiotics. Dutch incidence and cost estimates based on claims were consistent with previous estimates. Prevalence estimates were somewhat higher. Drug and hospital costs were highest shortly after the diagnosis. Healthcare consumption related to comorbidities was in-line with the previously reported comorbidity estimates.

References

May 13, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·G KobeltB Jönsson
Mar 7, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Laurence JasseCaroline Tilikete
Sep 28, 2013·BMC Neurology·Elaine KingwellRuth Ann Marrie
Jan 28, 2015·Multiple Sclerosis : Clinical and Laboratory Research·Ruth Ann MarrieNadia Reider
Sep 17, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A P LysandropoulosUNKNOWN ParadigMS Group
Sep 22, 2015·Journal of Comparative Effectiveness Research·James M Brophy
Apr 27, 2017·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Shachar Moshe AharonyJacques Corcos
Jun 24, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Bernard UitdehaagUNKNOWN European Multiple Sclerosis Platform

❮ Previous
Next ❯

Citations

Jan 21, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Pia M Vidal, Rodrigo Pacheco
Sep 29, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Dirk SchrieferTjalf Ziemssen

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Archivos de bronconeumología
M Mar Palacio NebredaDavid Martínez Hernández
Schweizer Archiv für Neurologie und Psychiatrie = Archives suisses de neurologie et de psychiatrie = Archivio svizzero di neurologia e psichiatria : offizielles Organ der Schweizerischen Neurologischen Gesellschaft und der SchweizerischenGesellschaft für
S Huber, V Henn
© 2022 Meta ULC. All rights reserved